In the past 20 years, the emergence of biological agents including interleukin 6 (IL-6) inhibitors, costimulatory modulators, B cell depleting drugs as well as tumor necrosis factor (TNF) inhibitors has changed the original treatment strategy and fundamentally Changed the course of rheumatoid arthritis (Crossfield et al., 2021). The gene discussed is IL6; the disease is rheumatoid arthritis.